Alcohol UseMATAspireNCT06553196
MATAspire: Mental Health Awareness Tailored App for Substance Prevention and Integrated Resilience Education
A study testing MATAspire Web-app in people with Alcohol Use and Cannabis Use, run by California State University, Northridge at 1 site in United States.
Trial summary
The MATAspire intervention is a web-app designed to promote substance misuse prevention education and bolster protective coping skills whereby students complete six weekly interactive modules using a smart device or computer. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Alcohol Use, Cannabis Use, Nicotine Use
- What is being tested?
- MATAspire Web-app
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,000 participants
- Where
- 1 siteUnited States
- Study dates
- 24 Aug 2024to 31 Dec 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Current Cal State Northridge (CSUN) matriculated students with active CSUN email
- Age 18 and older
Who cannot join
- Not currently a CSUN student
- CSUN students under the age of 18 years
- Have previously participated in this study
- Identified as having an alcohol or substance use disorder (AUD or SUD) as determined by the brief Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 screener
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
California State University, Northridge (CSUN)
Northridge, California, 91330
Bethany Rainisch, PhD, MPH, 8186774081, bethany.rainisch@csun.edu
Linn Dahlman, 8186775397, linn.dahlman@csun.edu
About this study
The MATAspire intervention is a web-app designed to promote substance misuse prevention education and bolster protective coping skills whereby students complete six weekly interactive modules using a smart device or computer. Each module is approximately 15-20 minutes long and focuses on select substances and coping strategies: (i) adaptive coping strategies, (ii) alcohol, (iii) cannabis, (iv) nicotine, (v) prescription drugs and opioids, (vi) final module. The modules are based on key theoretical constructs, behavior change strategies, and practical module components: attitudes (knowledge), perceived susceptibility (risk perceptions), and subjective norms (normative re-education). The intervention will be evaluated via a time series design using a sample of (~1000 students) randomly assigned to either the intervention or the control conditions at a public institution in Southern California.
- Being tested
- MATAspire Web-app
- Medical subject headings
- Alcohol Drinking, Opioid-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MATAspire Web-appBehavioural
Substance misuse prevention education and adaptive coping skills
| Study group | Role | What they receive |
|---|---|---|
| Prevention group | Experimental | Web-app with 6 weekly coping \& substance modules Receives: Behavioral: MATAspire Web-app |
| Control Group | No intervention | No access to web-app |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline alcohol use behavior at 3 months
Measured as the number of days drinking alcohol in past 30-days
Measured: Baseline and 90-days following intervention completion
Change from baseline binge drinking at 3 months
Measured as the number of days consumed five or more alcoholic beverages at the same time for males; four or more for females in past 30-days
Measured: Baseline and 90-days following intervention completion
Change from baseline cannabis use at 3 months
Measured as the number of days smoking, vaping, dabbing, oral (edibles/gummies/drinks), sprays, tinctures, and topically in past 30-days
Measured: Baseline and 90-days following intervention completion
Change from baseline nicotine use at 3 months
Measured as the number of days using menthol cigarettes, regular cigarettes, loose tobacco rolled into cigarettes or cigars, pipe tobacco, snuff, chewing tobacco, dipping tobacco, snus, and others in past 30-days
Measured: Baseline and 90-days following intervention completion
Change from baseline electronic vape use products at 3 months
Measured as the number of days using vaporizers, vape pens, hookah pens, electronic cigarettes, e-pens, or electronic nicotine delivery systems in past 30-days
Measured: Baseline and 90-days following intervention
Change from baseline non-prescribed prescription drug use behavior at 3 months
Measured as the number of days used stimulants, sedatives, benzodiazepines, and prescription opioids in past 30-days
Measured: Baseline and 90-days following intervention completion
Change from baseline coping skills at 3 months
Measured as the degree of effective and ineffective ways to cope with a stressful life event in ...
Measured: Baseline and 90-days following intervention completion
Secondary outcomes (4)
Change from baseline alcohol use related outcomes at 3 months
Measured as participants who report any past 30-day alcohol use indicate how many times they have experienced select outcomes in the last 30 days while drinking alcohol, or as a result of their alcohol use
Measured: Baseline and 90-days following intervention completion
Change from baseline nicotine use related outcomes at 3 months
Measured as participants who report any past 30-day nicotine use indicate how many times they have experienced ten select outcomes in the last 30 days while using nicotine, or as a result of their nicotine use.
Measured: Baseline and 90-days following intervention completion
Change from baseline cannabis use related outcomes at 3 months
Measured as participants who report any past 30-day cannabis use indicate how many times they have experienced ten select outcomes in the last 30 days while using cannabis, or as a result of their cannabis use
Measured: Baseline and 90-days following intervention completion
Change from baseline non-prescribed prescription drug use related outcomes at 3 months
Measured as participants who report any past 30-day non-prescribed prescription drug use indicate how many times they have experienced ten select outcomes in the last 30 days while using prescription drugs not prescribed to them, or for the purpose of feeling or experiencing something
Measured: Baseline and 90-days following completion of intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2024
- Study start24 Aug 2024
- Primary completion15 May 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alcohol UseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- California State University, Northridge
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bethany Rainisch, California State University, Northridge
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06553196
- Sponsor's protocol ID
- H79SP083737
- Acronym
- MATAspire
- Status last verified
- Mar 2026
- First submitted
- 8 Aug 2024
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No